Woodline Partners’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Woodline Partners’s Portfolio EFTRW Stock Details EFTRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-93,922	Closed	-$94K	–	756
2021 Q2	$94K	Hold	93,922	–	–	﹤0.01%	506
2021 Q1	$57K	Buy	+93,922	New	+$90.6K	﹤0.01%	415

Other funds holding EFTRW

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Woodline Partners's EFTRW Position: Q3 2021 in Review

Woodline Partners sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2021, closing a stake of 93,922 shares — an estimated $94K sold.

Woodline Partners first reported a position in EFTRW in Q1 2021 and held it in 2 quarters. The position peaked at $94K in Q2 2021. 21 funds tracked by Wall St. Rank hold EFTRW as of Q3 2021.

Woodline Partners reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2021 after selling out during the quarter.
Woodline Partners sold 93,922 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2021, an estimated $94K.
Woodline Partners first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q1 2021 and held it in 2 quarters.
Woodline Partners's eFFECTOR Therapeutics, Inc. Warrant position peaked at $94K in Q2 2021.
21 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2021.

Based on Woodline Partners's 13F filing for Q3 2021, filed 15 Nov 2021.